Insights

Why Ascendis Pharma Stock Is Sinking Today

What happened
Shares of Ascendis Pharma (NASDAQ: ASND) were down by 10.5% as of 12:10 p.m. ET Thursday. The decline came after the drugmaker announced its first-quarter results following the market close on Wednesday.
The Denmark-based multinational reported Q1 revenue of 6.8 million euros, a big jump from revenue of 700,000 euros in the prior-year period. However, the company posted a net loss of 125.5 million euros, or 2.21 euros per share. This result was worse than the consensus estimate.
So what
Biotech stocks usually fall on earnings misses. It didn’t help matters that Ascendis is having to shift some of its clinical trials from Ukraine, Russia, and Belarus. However, there were some positive takeaways from the company’s Q1 update that could be easily overlooked.
Importantly, payer coverage of growth hormone Skytrofa (TransCon) jumped to 45% of U.S. lives by the end of April from around 36% at the end of February. Ascendis also won marketing authorization in the European Union for the drug to be used as a treatment for children and adolescents ages 3 to 18. 
Image source: Getty Images.

Now what
Ascendis could have multiple positive catalysts coming in the not-too-distant future. The company remains on track to file for U.S. approval of TransCon as a treatment for adults with hyperparathyroidism in the third quarter. An EU submission is expected in the fourth quarter.
Several key clinical updates are also on the way. Ascendis anticipates reporting results in the fourth quarter from a phase 2 study of TransCon in treating children ages 2 to 10 with achondroplasia. Results from two phase 1/2 studies of TransCon targeting solid tumors are expected in Q3 and Q4.
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Shares of Ascendis Pharma (NASDAQ: ASND) were down by 10.5% as of 12:10 p.m. ET Thursday. The decline came after the drugmaker announced its first-quarter results following the market close on Wednesday.

The Denmark-based multinational reported Q1 revenue of 6.8 million euros, a big jump from revenue of 700,000 euros in the prior-year period. However, the company posted a net loss of 125.5 million euros, or 2.21 euros per share. This result was worse than the consensus estimate.

So what

Biotech stocks usually fall on earnings misses. It didn’t help matters that Ascendis is having to shift some of its clinical trials from Ukraine, Russia, and Belarus. However, there were some positive takeaways from the company’s Q1 update that could be easily overlooked.

Importantly, payer coverage of growth hormone Skytrofa (TransCon) jumped to 45% of U.S. lives by the end of April from around 36% at the end of February. Ascendis also won marketing authorization in the European Union for the drug to be used as a treatment for children and adolescents ages 3 to 18. 

Image source: Getty Images.

Now what

Ascendis could have multiple positive catalysts coming in the not-too-distant future. The company remains on track to file for U.S. approval of TransCon as a treatment for adults with hyperparathyroidism in the third quarter. An EU submission is expected in the fourth quarter.

Several key clinical updates are also on the way. Ascendis anticipates reporting results in the fourth quarter from a phase 2 study of TransCon in treating children ages 2 to 10 with achondroplasia. Results from two phase 1/2 studies of TransCon targeting solid tumors are expected in Q3 and Q4.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!